BPD Prescribing: A PMHNP Reality Check for 2026

Why BPD prescribing matters in 2026

BPD prescribing in 2026 starts with one stark fact: zero medications are FDA-approved to treat borderline personality disorder. Yet a 2024 review found patients with BPD carry an average of three to five concurrent psychotropics, usually started one at a time and never stopped. As a result, BPD prescribing has drifted far from the evidence base.

The American Psychiatric Association’s 2024 practice guideline — the first major BPD update in two decades — draws a hard line. No pharmacotherapy treats the core illness. Most of what has been prescribed for years does not help.

However, that leaves new PMHNPs in a bind. Specifically, the patient in room two is dysregulated, self-harming, and asking for a refill on four medications the chart does not justify. On one hand, saying no feels unsafe. On the other hand, saying yes keeps the prescribing pad moving and the problem growing.

Therefore, this guide walks through the 2026 PMHNP-level answer: what the APA actually recommends, which target symptoms respond to which class, the mistakes that drive polypharmacy, and a structured reconciliation cadence that protects both the patient and the license.

The new APA rules on BPD prescribing

The 2024 APA practice guideline — approved by the Board of Trustees in December 2023 and published in the American Journal of Psychiatry on November 1, 2024 — says three things PMHNPs need to memorize.

One. No medication is recommended to treat the core symptoms of BPD. The evidence across four decades of trials, including the 2022 Cochrane review, shows no reliable effect on overall severity.

Two. Clinicians should keep any psychotropic used in BPD time-limited and target it at a specific, measurable symptom — affective dysregulation, impulsive aggression, or cognitive-perceptual disturbance. Not “stabilization.” Not “mood.”

Three. Clinicians must complete a full medication review and reconciliation for every patient at least every six months, with the clear goal of finding what to taper.

“New grads inherit these patients already on four medications. The instinct is to add a fifth. The 2024 guideline makes it clear — the clinical skill is to subtract. Every refill is a choice, not a default,” says Lindsay Hill, DNP, PMHNP-BC.

In short, structured psychotherapy — DBT, mentalization-based therapy, transference-focused psychotherapy, schema therapy — is the core treatment. Medication is adjunctive, short-term, and accountable to a specific symptom it was started to address.

BPD prescribing by target symptom: match the drug to the symptom, not the label

When pharmacotherapy is appropriate — usually for an acute crisis, a co-occurring illness, or a clear target symptom — the evidence falls into three narrow lanes.

Impulsive aggression and anger. Second-generation antipsychotics show the strongest effect here. Specifically, aripiprazole has the best signal-to-tolerability ratio in meta-analytic data, with modest reductions in anger and impulsivity at 10–15 mg. However, olanzapine works but carries metabolic cost most early-career patients cannot afford long-term.

Affective dysregulation. Certain mood stabilizers — lamotrigine, topiramate, valproate — reduce affective instability and anger in trials. In particular, lamotrigine is most forgiving on weight and cognition; titration to 100–200 mg takes eight weeks minimum. Meanwhile, valproate requires teratogenicity counseling for any patient of reproductive age.

Cognitive-perceptual symptoms. Transient psychotic-like experiences, dissociation, and paranoid ideation respond to low-dose antipsychotics — quetiapine 50–150 mg, aripiprazole 5–10 mg — for short courses. Not maintenance.

However, SSRIs, despite being the most prescribed class for BPD, do not belong in any of these lanes unless the patient has a clearly diagnosed comorbid MDD, OCD, or PTSD. The 2024 guideline calls this out directly: do not initiate an SSRI for BPD itself.

Likewise, benzodiazepines belong on the do-not-start list. They worsen impulsivity, increase self-harm, and produce dependence patterns that are exceptionally difficult to unwind in this population.

BPD prescribing mistakes: what most people get wrong

First, the most common mistake is treating BPD like depression with extra steps. A patient presents with tearfulness and hopelessness, the clinician starts an SSRI, nothing improves at week six, then adds a second agent, then a sleep medication, and finally a mood stabilizer for “irritability.” Six months later the chart lists five drugs and the patient is no better.

Second, the mistake is starting antipsychotics for “mood stabilization” without a defined target. The chart says “quetiapine 300 mg at bedtime for mood.” That is not a target symptom — that is a sedation plan. Two years in, the patient has gained 40 pounds, has metabolic syndrome, and still meets full criteria for BPD.

Third, the mistake is confusing tolerance of the clinician with clinical improvement. Patients with BPD often report feeling “better” on medications that sedate or numb their feelings. That is not remission — it is numbness. Measurable symptom change is the standard, not patient report alone.

Therefore, the fix is a target-symptom contract at the first prescription. Document what the drug is for, what improvement looks like, and the date by which the trial ends if the target has not moved. In other words, anything without that contract is polypharmacy by default.

BPD prescribing monitoring: the six-month reconciliation rule

Indeed, the APA guideline’s most actionable recommendation is the six-month medication review. Every BPD patient needs a full reconciliation at or before the six-month mark, with a written disposition for each prescription — continue, taper, or discontinue.

Specifically, the review asks four questions per medication. What target symptom was this started for? Has the symptom measurably improved? If yes, is the treatment still time-limited? If no, what is the taper plan?

Additionally, monitoring beyond the six-month audit should match the agent. Second-generation antipsychotics require metabolic panels — fasting glucose, lipids, weight — at baseline, 12 weeks, and annually. Lamotrigine requires rash counseling for the first eight weeks. Valproate requires liver function and pregnancy testing. Clinicians should run an AIMS exam on every antipsychotic at any dose, both at baseline and every six months.

Importantly, deprescribing is clinical skill, not capitulation. Taper one agent at a time, over weeks not days, and document the target symptom’s trajectory as the medication comes off. Notably, most patients do not destabilize on a thoughtful taper — they become more engaged in therapy.

Where psychotherapy fits

The 2024 guideline names a structured psychotherapy approach as the core treatment for BPD across adolescents and adults. In particular, dialectical behavior therapy has the longest evidence base and the best real-world availability. Likewise, mentalization-based therapy, transference-focused psychotherapy, schema therapy, and general psychiatric management all show efficacy in randomized trials.

However, PMHNPs rarely deliver these modalities directly, but the prescribing visit either connects a patient to therapy or strands them on a medication merry-go-round. Every BPD visit should end with a therapy referral or a documented plan to obtain one, and every med review should treat “not in therapy” as a treatment failure — because the guideline does.

Meanwhile, where access is limited, brief psychoeducation on emotion regulation, distress tolerance, and interpersonal effectiveness — the four DBT modules — still produces measurable benefit in under-resourced settings. Ultimately, a 10-minute teach-back on a specific skill at each follow-up does not replace DBT, but it outperforms adding another milligram.

The bottom line. BPD does not respond to medication the way depression or psychosis does. Prescribing well in this population means prescribing less, tying every agent to a measurable target, and treating the six-month review as a deprescribing opportunity. The clinicians who master this approach protect their patients, their licenses, and their own clinical judgment.

The next step is to audit one BPD patient’s current medication list this week against a target-symptom contract — and build the deprescribing plan from there.

This content is for educational purposes and does not replace individualized clinical judgment or supervision.